PTO WILL NOT ADD WAXMAN/HATCH TIME TO GATT 20-YEAR PATENT TERMS; DECISION DOES NOT AFFECT CAPOTEN, ZANTAC BUT WILL REDUCE NUMBER OF EXTENDED PATENTS
Pharmaceutical patents that were in force on June 8 will not have Waxman/Hatch extensions added on to the new 20-year terms set by the Uruguay Round Agreements Act, the Patent & Trademark Office ruled in a Federal Register notice published June 7.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth